Zobrazeno 1 - 10
of 41
pro vyhledávání: '"Ewen Cummins"'
Autor:
Asra Asgharzadeh, Mubarak Patel, Martin Connock, Sara Damery, Iman Ghosh, Mary Jordan, Karoline Freeman, Anna Brown, Rachel Court, Sharin Baldwin, Fatai Ogunlayi, Chris Stinton, Ewen Cummins, Lena Al-Khudairy
Publikováno v:
Health Technology Assessment, Vol 28, Iss 80 (2024)
Background Hybrid closed-loop systems are a new class of technology to manage type 1 diabetes mellitus. The system includes a combination of real-time continuous glucose monitoring from a continuous glucose monitoring device and a control algorithm t
Externí odkaz:
https://doaj.org/article/9b96c032b3b34fcbb0afe467cd54e122
Autor:
Rhona Johnston, Olalekan Uthman, Ewen Cummins, Christine Clar, Pamela Royle, Jill Colquitt, Bee Kang Tan, Andrew Clegg, Saran Shantikumar, Rachel Court, J Paul O’Hare, David McGrane, Tim Holt, Norman Waugh
Publikováno v:
Health Technology Assessment, Vol 21, Iss 2 (2018)
Externí odkaz:
https://doaj.org/article/b154ad873e2544258b9edb28ab68922a
Autor:
Rhona Johnston, Olalekan Uthman, Ewen Cummins, Christine Clar, Pamela Royle, Jill Colquitt, Bee Kang Tan, Andrew Clegg, Saran Shantikumar, Rachel Court, J Paul O’Hare, David McGrane, Tim Holt, Norman Waugh
Publikováno v:
Health Technology Assessment, Vol 21, Iss 2 (2017)
Background: Most people with type 2 diabetes are overweight, so initial treatment is aimed at reducing weight and increasing physical activity. Even modest weight loss can improve control of blood glucose. If drug treatment is necessary, the drug of
Externí odkaz:
https://doaj.org/article/1f9dc711b4bd44fc9bd1755140799fcb
Autor:
Karoline Freeman, Martin Connock, Ewen Cummins, Tara Gurung, Sian Taylor-Phillips, Rachel Court, Mark Saunders, Aileen Clarke, Paul Sutcliffe
Publikováno v:
Health Technology Assessment, Vol 19, Iss 91 (2015)
Background: 5-Fluorouracil (5-FU) is a chemotherapy used in colorectal, head and neck (H&N) and other cancers. Dose adjustment is based on body surface area (BSA) but wide variations occur. Pharmacokinetic (PK) dosing is suggested to bring plasma lev
Externí odkaz:
https://doaj.org/article/e62c18515da7474e96c5216b305c82f3
Autor:
Norman Waugh, Ewen Cummins, Saran Shantikumar, Jill L Colquitt, Andrew Clegg, J. Paul O'Hare, P Royle, Tim Holt, Olalekan A. Uthman, Christine Clar, Rachel Court, R Johnston, Bee K. Tan, David McGrane
Publikováno v:
Health Technology Assessment, Vol 21, Iss 2 (2017)
Background Most people with type 2 diabetes are overweight, so initial treatment is aimed at reducing weight and increasing physical activity. Even modest weight loss can improve control of blood glucose. If drug treatment is necessary, the drug of f
Autor:
Ewen Cummins, Pamela Royle, R Johnston, Xavier Armoiry, Jeremy N. Rodrigues, Andrew J. Metcalfe, Hema Mistry, Martin Connock, Norman Waugh
Chondrosphere (Spherox) is a form of autologous chondrocyte implantation (ACI). It is licensed for repair of symptomatic articular cartilage defects of the femoral condyle and the patella of the knee with defect sizes up to 10 cm2 in adults. In a sin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b9a15132511030ab44dedf4fbc8271b6
https://ora.ox.ac.uk/objects/uuid:be6af362-9b56-48d9-b951-4f01535dceea
https://ora.ox.ac.uk/objects/uuid:be6af362-9b56-48d9-b951-4f01535dceea
Autor:
Martin Connock, Alexander Tsertsvadze, Aileen Clarke, Pamela Royle, Xavier Armoiry, G. J. Melendez-Torres, Ewen Cummins
Ixazomib is an oral proteasome inhibitor used in combination with lenalidomide plus dexamethasone (IXA-LEN-DEX) and licensed for relapsed or refractory multiple myeloma. As part of a single technology appraisal (ID807) undertaken by the National Inst
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::191d02d634837feecf63382c23708d85
http://wrap.warwick.ac.uk/100477/1/WRAP-Ixazomib-relapsed-refractory-multiple-myeloma-Armoiry-2018.pdf
http://wrap.warwick.ac.uk/100477/1/WRAP-Ixazomib-relapsed-refractory-multiple-myeloma-Armoiry-2018.pdf
Publikováno v:
The European Journal of Health Economics. 13:801-809
Golimumab is a novel TNF-α inhibitor licensed to treat patients with active PsA. Although its clinical efficacy has been proven in clinical trials, its cost effectiveness is yet to be established.To estimate the cost effectiveness of golimumab among
Autor:
Sian Taylor-Phillips, Paul Sutcliffe, Tara Gurung, Mark Saunders, Ewen Cummins, Aileen Clarke, Rachel Court, Martin Connock, Karoline Freeman
Publikováno v:
Health Technology Assessment, Vol 19, Iss 91 (2015)
Background5-Fluorouracil (5-FU) is a chemotherapy used in colorectal, head and neck (H&N) and other cancers. Dose adjustment is based on body surface area (BSA) but wide variations occur. Pharmacokinetic (PK) dosing is suggested to bring plasma level
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::69f9f85e21b14aa61ede3c42b1d8e6b1
https://europepmc.org/articles/PMC4781223/
https://europepmc.org/articles/PMC4781223/
Autor:
Ramesh P. Arasaradnam, Ngianga-Bakwin Kandala, Christine Clar, Pamela Royle, Ewen Cummins, D Shyangdan, Norman Waugh, R Johnston
Publikováno v:
Health Technology Assessment, Vol 17, Iss 55 (2013)
Irritable bowel syndrome (IBS) is common, and causes pain, bloating and diarrhoea and/or constipation. It is a troublesome condition that reduces the quality of life but causes no permanent damage. Inflammatory bowel disease (IBD) comprises mainly ul